Relay Therapeutics, Inc. RLAY
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 23.86% | 39.04% | 53.45% | -16.49% | -76.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.86% | 39.04% | 53.45% | -16.49% | -76.27% |
| Cost of Revenue | -3.51% | -16.45% | -17.69% | -16.89% | -15.47% |
| Gross Profit | 4.35% | 17.87% | 20.02% | 16.90% | 8.20% |
| SG&A Expenses | -28.70% | -35.91% | -27.14% | -18.31% | -7.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.72% | -20.44% | -19.61% | -17.17% | -13.99% |
| Operating Income | 9.51% | 21.64% | 21.50% | 17.18% | 8.12% |
| Income Before Tax | 8.19% | 18.20% | 18.13% | 13.79% | 3.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.19% | 18.20% | 18.13% | 13.79% | 3.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.19% | 18.20% | 18.13% | 13.79% | 3.49% |
| EBIT | 9.51% | 21.64% | 21.50% | 17.18% | 8.12% |
| EBITDA | 8.85% | 21.30% | 21.31% | 17.12% | 8.08% |
| EPS Basic | 19.60% | 29.89% | 32.76% | 33.03% | 22.77% |
| Normalized Basic EPS | 19.61% | 32.48% | 35.45% | 35.88% | 26.44% |
| EPS Diluted | 19.60% | 29.89% | 32.76% | 33.03% | 22.77% |
| Normalized Diluted EPS | 19.61% | 32.48% | 35.45% | 35.88% | 26.44% |
| Average Basic Shares Outstanding | 12.41% | 14.32% | 20.14% | 28.67% | 26.91% |
| Average Diluted Shares Outstanding | 12.41% | 14.32% | 20.14% | 28.67% | 26.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |